Can Cardio Firms Curb M&A? Selective Seeding Is Combo Product Strategy
This article was originally published in The Gray Sheet
Executive Summary
Large cardiovascular device firms maintain they will exercise discipline in forming strategic alliances with biotech and IT companies, although such deals are considered key to sustainable growth